Interleukin-5-producing group 2 innate lymphoid cells control eosinophilia induced by interleukin-2 therapy.

@article{Gool2014Interleukin5producingG2,
  title={Interleukin-5-producing group 2 innate lymphoid cells control eosinophilia induced by interleukin-2 therapy.},
  author={Fr{\'e}d{\'e}ric Van Gool and Anna V Molofsky and Malika M. Morar and Michelle Rosenzwajg and H J Liang and David Klatzmann and Richard M Locksley and Jeffrey A Bluestone},
  journal={Blood},
  year={2014},
  volume={124 24},
  pages={3572-6}
}
Interleukin (IL)-2 promotes regulatory T-cell development and function, and treatment with IL-2 is being tested as therapy for some autoimmune diseases. However, patients receiving IL-2 treatment also experience eosinophilia due to an unknown mechanism. Here, we show that patients receiving low-dose IL-2 have elevated levels of serum IL-5, and this correlates with their degree of eosinophilia. In mice, low-dose IL-2-anti-IL-2 antibody complexes drove group 2 innate lymphoid cells (ILC2) to… CONTINUE READING